Janumet 1000mg/50mg Tablet is a combination oral antidiabetic medication containing Sitagliptin 50mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the incretin system by increasing levels of active incretin hormones, thereby improving glucose-dependent insulin secretion and reducing glucagon release. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity. The synergistic action of these agents effectively lowers blood glucose levels, aiding in glycemic control when diet and exercise alone are insufficient. Janumet is prescribed as part of a comprehensive diabetes management plan and may be used as initial therapy or as an adjunct to other antidiabetic agents. It is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which typically subside with continued use. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Janumet should be used cautiously in patients with risk factors for lactic acidosis and under medical supervision to optimize therapeutic outcomes and minimize potential risks.